BioSpace · May 2025
HepaTx received an NIH/NIDDK Phase I SBIR grant for a proteomic assay to monitor transplanted cells and tissues, supporting its cell-therapy monitoring platform.
Company research
Public company, workplace, funding, and market signals
Overview
HepaTx is a Palo Alto biotech developing off-the-shelf, stem-cell-based regenerative medicine therapies for late-stage liver disease as an alternative to liver transplant. Public databases disagree on funding totals, so the figures below reflect mixed public sources rather than a single source of truth.
Primary product
Hx-001, an off-the-shelf hepatocyte-like cell therapy for late-stage liver disease
Founded
2015
Headquarters
Palo Alto, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Cell therapy / regenerative medicine
Offices
P.O. Box 60850, Palo Alto, CA 94306, United States
2493 Waverley St, Palo Alto, CA, United States
Palo Alto, CA 94301, United States
Palo Alto, CA 94020, United States
Business model
cell therapy development
licensed IP / platform partnerships
grant-funded R&D
Funding
Stage
preclinical, grant-backed
Total raised
$7M
Latest round
Grant · May 2025
Latest amount
$176K
People & investors
Work & culture
Mission-driven and highly scientific, with a Stanford-connected network of advisors and a patient-focused message around making liver regeneration clinically and economically practical.
Product & market
Differentiators
- —off-the-shelf therapy instead of donor-dependent transplant
- —scalable, fully-defined manufacturing
- —on-demand availability
- —does not genetically modify cells
- —exclusive worldwide Stanford license
- —broad liver-disease pipeline spanning niche and large indications
Technology
adipose-derived stem cells
hepatocyte-like cells
allogeneic cell therapy
proteomic assay for cell monitoring
single-cell genomics collaboration
licensed Stanford IP
Competitors
LyGenesis
Surrozen
Cellaion
Ambys Medicines
eGenesis
Satellite Bio
Promethera Biosciences
Madrigal Pharmaceuticals
Intercept Pharmaceuticals
Nimbus Therapeutics
Scale & contact
Estimated revenue
about $5M estimated annual revenue
Estimated monthly visits
1.1K
Traffic estimate as of Nov 2025
Latest news
PR Newswire · Sep 2024
HepaTx signed a license agreement with Mayo Clinic to advance its stem-cell technology into clinical trials, initially for alcohol-related hepatitis.
BioSpace · Sep 2023
HepaTx announced a Canadian patent covering methods and compositions for producing hepatocyte-like cells, extending its IP estate.
PR Newswire · May 2022
The USPTO granted HepaTx a patent covering its hepatocyte-like cell manufacturing technology from adipose-derived stromal cells.
PR Newswire · Mar 2022
HepaTx said the Japanese Patent Office decided to grant protection for its hepatocyte-like cell technology, strengthening its IP position.
Jobs and careers at Hepatx
0 jobs at Hepatx
No open positions
Check back later for new openings